These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11092432)

  • 1. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors.
    Meigs JB
    Am J Epidemiol; 2000 Nov; 152(10):908-11; discussion 912. PubMed ID: 11092432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
    Sakkinen PA; Wahl P; Cushman M; Lewis MR; Tracy RP
    Am J Epidemiol; 2000 Nov; 152(10):897-907. PubMed ID: 11092431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.
    Vlassara H; Cai W; Tripp E; Pyzik R; Yee K; Goldberg L; Tansman L; Chen X; Mani V; Fayad ZA; Nadkarni GN; Striker GE; He JC; Uribarri J
    Diabetologia; 2016 Oct; 59(10):2181-92. PubMed ID: 27468708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperinsulinemia--the common denominator in type II diabetes mellitus,obesity, hypertension, hypertriglyceridemia and atherosclerosis].
    Málková J; Andĕl M; Stolba P; Kimlová I
    Cas Lek Cesk; 1994 Jan; 133(2):41-5. PubMed ID: 8131178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic concomitants of syndrome X.
    McCarty MF
    Med Hypotheses; 1995 Mar; 44(3):179-93. PubMed ID: 7609672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Syndrome X, at the crossroads of metabolic and cardiovascular diseases].
    Scheen AJ
    Rev Med Liege; 1998 Jan; 53(1):29-32. PubMed ID: 9555180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and the metabolic syndrome.
    Johannsson G; Bengtsson BA
    J Endocrinol Invest; 1999; 22(5 Suppl):41-6. PubMed ID: 10442570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular syndromes X, endothelial dysfunction and insulin resistance.
    Goodfellow J; Owens D; Henderson A
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S163-71. PubMed ID: 8864655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review.
    Chang YH; Chang DM; Lin KC; Shin SJ; Lee YJ
    Diabetes Metab Res Rev; 2011 Sep; 27(6):515-27. PubMed ID: 21484978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenesis of atherosclerosis in diabetes mellitus. The role of insulin resistance and hyperinsulinemia].
    Kostiuk Ep; Zubkova ST
    Fiziol Zh (1978); 1993; 39(5-6):93-8. PubMed ID: 8045324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome as a cardiovascular risk factor.
    Krone W; Meinertz T
    Herz; 1995 Feb; 20(1):2-4. PubMed ID: 7713474
    [No Abstract]   [Full Text] [Related]  

  • 16. [Metabolic syndrome and type II diabetes].
    Fessler B
    Med Monatsschr Pharm; 1992 Oct; 15(10):312-3. PubMed ID: 1406442
    [No Abstract]   [Full Text] [Related]  

  • 17. Endothelial dysfunction in metabolic and vascular disorders.
    Polovina MM; Potpara TS
    Postgrad Med; 2014 Mar; 126(2):38-53. PubMed ID: 24685967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome?
    Serné EH; de Jongh RT; Eringa EC; Ijzerman RG; de Boer MP; Stehouwer CD
    Essays Biochem; 2006; 42():163-76. PubMed ID: 17144887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-pharmacological therapy of metabolic syndrome].
    Wirth A
    Herz; 1995 Feb; 20(1):56-69. PubMed ID: 7713478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.